A late entry using a method usually reserved for kidnapping and ransom notes- but still good Barts Experimental Cancer Medicine Centre OncoAlert Toni Choueiri, MD Brian Rini, MD

Kristen you are inspiring ❤️

Amazing #ESMO24 GU highlights by Uromigos in their recent episode with Brian Rini, MD Tom Powles silke gillessen . Will be an interesting conference this year. podcasts.apple.com/gb/podcast/the…

Now that EV+pembro is approved by FDA & EMA, we need to build this knowledge before prematurely defining strict criteria.

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

We have a @uromigos Nashville 24 golden ticket 🎫 winner Dimitra Bakaloudi MD, MS for 27th and 28th Sept 👏👏☀️☀️. Session include MIBC, new ADCs, papillary RCC, cellular therapies and the Uromigos cup with 🇯🇵 and Tres Uramigas 🇺🇸 🇪🇸 🇲🇽 teams . New trial designs and defining oligomet RCC…

Excited that my “pastamigos” entry won the golden ticket 🎫 for the Uromigos live in Nashville 😃 Looking forward to the amazing sessions and of course the uromigos cup🏆 Tom Powles Brian Rini, MD Petros Grivas Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Shilpa Gupta

📺Check out the exciting events in store for #UromigosLive2024 in Nashville! Follow us here on X and visit GUOncologyNow.com for updates: guoncologynow.com/conference/the… 📢 Live streaming of sessions starts 9/27 at 2:00pm ET!

spotifyanchor-web.app.link/e/i3PNDwhAPMb

Excited for Team Japan at #UromigosLive 2024! #ESMO2024 podcast from Uromigos Japan coming.. JCOG Naoto T Ueno, MD, PhD 第111回日本泌尿器科学会総会（公式）JUA2024 Official

Datos actualizados del estudio LITESPARK-005 con seguimiento >2 años. Se mantiene PFS, no beneficio en OS, no nuevos AEs Brian Rini, MD Toni Choueiri, MD Laurence Albiges Tom Powles Cris

SUNNIFORECAST: Nivo-Ipi vs SOC (principalmente TKis) en nccRCC aumenta tasa de OS a los 12 meses. No beneficio en PFS

LITESPARK-005 #ESMO2024 最終解析の結果、副次評価項目のOSはHR 0.92, P=0.18とネガティブ。3rd lineメインの設定におけるOSの意義をどのように考えるか？が今後の議論。

Katy Beckermann joins to discuss the TiNivo2 data presented at #ESMO2024. After this 2nd negative trial of IO after IO, is there ANY role for sequential IO in RCC? spotifyanchor-web.app.link/e/8ckUmvvqSMb

SUNNIFORECAST reported at #ESMO2024 providing data about the activity of Ipi/Nivo in Non-clear cell RCC. Lothar Bergmann joins us to discuss here: spotifyanchor-web.app.link/e/lBwBWqlsSMb

After the SUNNIFORECAST presentation at #ESMO2024, what is the standard of care for front-line, metastatic papillary RCC?

Exactly. The responsibility falls to providers to give patients therapy with maximal benefit/risk. If no benefit, then it’s all risk. The persistence of this practice in the face of negative data is the desperation to help patients, but in fact results in more harm.

TiNivo-2試験　#ESMO24 免疫チェックポイント阻害薬後の2nd, 3rd lineのTivo+Nivo vs. Tivo alone. PD-1阻害薬のbeyond PDはPFS、OS共に延長効果を示さず。

新規HIF-2αのNKT2152のPhase 1/2試験　#ESMO24 ORR, PD rate, 毒性などBelzutifanのデータと大きな変わりない。ただし、半減期が38日と非常に長いのが違い（Belzutifan の半減期は14時間）。

Uramiga silke gillessen with a great Presidential presentation. Podcast coming soon!!